What's the indication that Anrotini sold $3 billion in 19 years and the next reported production?

In 2019, Therotini's sales at PDB Sample Hospital will be 770 million yuan, taking into account a magnification of about four times, and the actual sales are expected to be around 3 billion yuan.
anrotinib is likely to be a chinese biopharmaceutical super-hot product in the future, and some industry insiders predict that Anrotinib will become the first domestic ally with annual sales of more than 5 billion.
so there are 3 indications listed, 1 indicationisis in the NDA stage, the next report of the indications will be what? 3 indications have been approved, 1 indications NDA hydrochloric acid anrotinib (commodity name: Fucovi) is a new type of new drug developed by Zhengda Qing, is a new type of small molecule multi-target tyrosine kinase inhibitor, can effectively inhibit VEGFR, PDGFR, C-Kit and other kinase, with anti-tumor oxidation and tumor growth.
, Anrotinico at the same time, VEGFR, FGFR1-4, PDGFR alpha/beta, c-KIT and other signaling pathways blocked, to achieve multi-directional inhibition of tumor angiogenesis and promote apoptosis and other effects.
the drug has a wide-spectrum anti-cancer effect in theory, and is therefore one of the most popular cancer targets.
Anrotini was first approved for non-small cell lung cancer (NSCLC) in May 2018 and currently has three indications approved and one of which is in the declared listing stage.
Anrotinib has been approved and declared listed for indications (Source: Corporate Bulletin, NMPA) In addition, Arotinib is recommended in the CSCO guidelines for primary lung cancer, soft tissue sarcoma and esophageal cancer due to deterministic clinical outcomes.
(Source: CSCO Guidelines) 1 indicationisis is included in health insurance 2018, Anrotini was negotiated into the national Category B health insurance directory, indications for third-line treatment of non-small cell lung cancer patients, medical insurance payment standard s487 yuan (12 mg/grain), 423.6 yuan (10 mg/grain) and 357 yuan (8 mg/grain). The
agreement is valid until 31 December 2020.
currently, only one indication is covered by health insurance.
is expected to hold a second health-care negotiation in November 2020.
is expected to cut prices in the second health-care negotiations in Anrotini by about 20 percent, given the price cuts already in place at the time of the first negotiations, and in light of the price reduction slashed in the second health-care negotiations of other varieties.
health-care negotiations at the end of this year could include approved new indications such as soft tissue sarcoma and small cell lung cancer, as well as approved thyroid myelin cancer.
multiple clinical trials are under way, the next report of indications or? Clinical trials of Anrotini include: (1) expanding indications, such as liver cancer, small cell ;( lung cancer, kidney cell cancer, thyroid myeloma, esophageal scale cancer, stomach cancer, etc.;
from some of the test data that have been disclosed, Anrotinib has shown anti-tumor ability in soft tissue sarcoma, renal cell carcinoma, small cell lung cancer and other tumor serombs.
anthrodeni partially disclosed clinical data combing (source: academic journals, ASCO) Anrotini in the study of indications there are several in clinical iii, such as combined chemotherapy first-line treatment of squamous, non-scaly non-small cell lung cancer, combined chemotherapy and PD-L1 (TQB2450) first-line treatment of a wide range of small cells Lung cancer; many in the second stage, such as the joint PD-1 (AK105) and bevabead singular first-line treatment of non-removable hepatocellular carcinoma, second-line treatment of renal cell carcinoma and differentiated thyroid cancer, the author speculates that the next reported indications are first-line treatment of small cell lung cancer, non-small cell lung cancer or differentiated thyroid cancer.
Anrotinib in research (Source: Drug Clinical Trial registration and information disclosure platform)